
CLAIMS

1. NOX inhibitor containing at least one methoxyflavone having a structure represented by the following formula (I):

[Formula 1]



(I)

(where R_1, R_4 and R_5 are each independently hydrogen or a methoxy group, and R_2 and R_3 are each a methoxy group).

2. The NOX inhibitor according to claim 1, wherein the at least one methoxyflavone is selected from group A consisting of 5,7,3',4'-tetramethoxyflavone, 3,5,7,3',4'-pentamethoxyflavone, 5,7-dimethoxyflavone, and 5,7,4'-trimethoxyflavone.

3. The NOX inhibitor according to claim 2, wherein a ratio of the total content of said methoxyflavones of group A to the total contents of said methoxyflavones of group A and methoxyflavones of group B consisting of 3,5,7-trimethoxyflavone, 3,5,7,4'-tetramethoxyflavone, 5-hydroxy-3,7,3',4'-tetramethoxyflavone, 5-hydroxy-7-methoxyflavone, 5-hydroxy-7,4'-dimethoxyflavone, 5-hydroxy-3,7-dimethoxyflavone, and 5-hydroxy-3,7,4'-trimethoxyflavone, which is expressed as A/(A+B), exceeds 0.65 on a molar basis.

4. An agent for preventing or treating an NOX-associated disease that contains said at least one methoxyflavone as defined in claim 1 or 2.


5. The agent according to claim 4, wherein the NOX-associated disease is selected

from the group consisting of allergic diseases, Parkinson's disease, cerebral infarction, cataract, epilepsy, spinal cord injury, arteriosclerosis, retinopathy of prematurity, renal disorder, peptic ulcer, pancreatitis, ulcerative colitis, myocardial infarction, adult respiratory distress syndrome, pulmonary emphysema, collagen diseases such as chronic rheumatoid arthritis, angiitis, edema, complications of diabetes, ultraviolet disorders, altitude sickness, porphyria, burns, frostbite, contact dermatitis, shock, failure of multiple organs, DIC, cancer, aging, fatigue, sarcopenia (progressive decline in skeletal muscle mass), mitochondrial dysfunction, dementia, and Alzheimer's disease.

6. The agent according to claim 4 or 5, wherein a ratio of the total content of said methoxyflavones of group A as defined in claim 2 to the total contents of said methoxyflavones of group A and said methoxyflavones of group B as defined in claim 3, which is expressed as A/(A+B), exceeds 0.65 on a molar basis.

7. NFκB inhibitor containing at least one methoxyflavone having a structure represented by the following formula (I):

[Formula 2]



(I)

(where R_1, R_4 and R_5 are each independently hydrogen or a methoxy group, and R_2 and R_3 are each a methoxy group).

8. The NFκB inhibitor according to claim 7, wherein the at least one methoxyflavone is selected from group A' consisting of 5,7,3',4'-tetramethoxyflavone, 5,7-dimethoxyflavone, and 5,7,4'-trimethoxyflavone.

9. The NFκB inhibitor according to claim 8, wherein a ratio of the total content of said methoxyflavones of group A' to the total contents of said methoxyflavones of group A' and methoxyflavones of group B' consisting of 3,5,7,3',4'-pentamethoxyflavone, 3,5,7-trimethoxyflavone, 3,5,7,4'-tetramethoxyflavone, 5-hydroxy-3,7,3',4'-tetramethoxyflavone, 5-hydroxy-7-methoxyflavone, 5-hydroxy-7,4'-dimethoxyflavone, 5-hydroxy-3,7-dimethoxyflavone, and 5-hydroxy-3,7,4'-trimethoxyflavone, which is expressed as A'/(A'+B'), exceeds 0.48 on a molar basis.

10. An agent for preventing or treating an NFκB-associated disease that contains said at least one methoxyflavone as defined in claim 7 or 8.

11. The agent according to claim 10, wherein the NFκB-associated disease is selected from the group consisting of rheumatoid arthritis, inflammatory colitis, osteoarthritis, osteolysis, tendinitis, sciatica, herniated disc, stenosis, myelosis, low back pain, zygapophyseal joint pain, carpal tunnel syndrome, tarsal tunnel syndrome, failed back surgery syndrome, AIDS, arteriosclerosis, asthma, arthritis, diabetes, inflammatory colitis, hepatitis, stroke, dementia, muscle wasting, viral infection, skin aging including photoaging, cancer, and aging.

12. The agent according to claim 10 or 11, wherein a ratio of the total content of said methoxyflavones of group A' as defined in claim 8 to the total contents of said methoxyflavones of group A' and said methoxyflavones of group B' as defined in claim 9, which is expressed as A'/(A'+B'), exceeds 0.48 on a molar basis.

13. NOX inhibitor containing 3',4'-dimethoxyflavone.

14. An agent for preventing or treating an NOX-associated disease that contains 3',4'-dimethoxyflavone.


15. The agent according to claim 14, wherein the NOX-associated disease is selected from the group consisting of allergic diseases, Parkinson's disease, cerebral infarction, cataract, epilepsy, spinal cord injury, arteriosclerosis, retinopathy of prematurity, renal disorder, peptic ulcer, pancreatitis, ulcerative colitis, myocardial infarction, adult respiratory distress syndrome, pulmonary emphysema, collagen diseases such as chronic rheumatoid

arthritis, angiitis, edema, complications of diabetes, ultraviolet disorders, altitude sickness, porphyria, burns, frostbite, contact dermatitis, shock, failure of multiple organs, DIC, cancer, aging, fatigue, sarcopenia (progressive decline in skeletal muscle mass), mitochondrial dysfunction, dementia, and Alzheimer's disease.

CLAIMS

1. NOX inhibitor comprising at least one methoxyflavone having a structure represented by the following formula (I):

[Formula 1]



(I)

(where R_1 is hydrogen, and R_4 and R_5 are each independently hydrogen or a methoxy group, and R_2 and R_3 are each a methoxy group),

wherein a ratio of the total content of methoxyflavones of group A to the total contents of said methoxyflavones of group A and methoxyflavones of group B, which is expressed as A/(A+B), exceeds 0.65 on a molar basis,

wherein said methoxyflavones of group A are selected from the group consisting of 5,7,3',4'-tetramethoxyflavone, 3,5,7,3',4'-pentamethoxyflavone, 5,7-dimethoxyflavone, and 5,7,4'-trimethoxyflavone, and

wherein said methoxyflavones of group B are selected from the group consisting of 3,5,7-trimethoxyflavone, 3,5,7,4'-tetramethoxyflavone, 5-hydroxy-3,7,3',4'-tetramethoxyflavone, 5-hydroxy-7-methoxyflavone, 5-hydroxy-7,4'-dimethoxyflavone, 5-hydroxy-3,7-dimethoxyflavone, and 5-hydroxy-3,7,4'-trimethoxyflavone.

2. NOX inhibitor comprising 3',4'-dimethoxyflavone.